Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug;64(6):466-80.
doi: 10.1177/0003319712464514. Epub 2012 Nov 4.

Therapeutic angiogenesis in critical limb ischemia

Geoffrey O Ouma  1 , Barak Zafrir, Emile R Mohler 3rd, Moshe Y Flugelman
Affiliations
Review

Therapeutic angiogenesis in critical limb ischemia

Geoffrey O Ouma et al. Angiology. 2013 Aug.

Abstract

Critical limb ischemia (CLI) is a severe form of peripheral artery disease associated with high morbidity and mortality. The primary therapeutic goals in treating CLI are to reduce the risk of adverse cardiovascular events, relieve ischemic pain, heal ulcers, prevent major amputation, and improve quality of life (QoL) and survival. These goals may be achieved by medical therapy, endovascular intervention, open surgery, or amputation and require a multidisciplinary approach including pain management, wound care, risk factors reduction, and treatment of comorbidities. No-option patients are potential candidates for the novel angiogenic therapies. The application of genetic, molecular, and cellular-based modalities, the so-called therapeutic angiogenesis, in the treatment of arterial obstructive diseases has not shown consistent efficacy. This article summarizes the current status related to the management of patients with CLI and discusses the current findings of the emerging modalities for therapeutic angiogenesis.

Keywords: cell therapy; critical limb ischemia; endovascular therapy; gene therapy; medical therapy; surgical therapy; therapeutic angiogenesis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Flugelman MY is the founder and President of MGVS Ltd, in Haifa, Israel, which develops cell-based therapies for vascular disorders including CLI.

References

    1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-society consensus for the management of peripheral arterial disease (TASC II) J Vasc Surg. 2007;45(suppl S):S5–S67. - PubMed
    1. Criqui MH. Peripheral arterial disease–epidemiological aspects. Vasc Med. 2001;6(3 suppl):3–7. - PubMed
    1. Becker F, Robert-Ebadi H, Ricco JB, et al. Chapter I: definitions, epidemiology, clinical presentation and prognosis. Eur J Vasc Endovasc Surg. 2011;42(suppl 2):S4–S12. - PubMed
    1. Egorova NN, Guillerme S, Gelijns A, et al. An analysis of the outcomes of a decade of experience with lower extremity revascularization including limb salvage, lengths of stay, and safety. J Vasc Surg. 2011;51(4):878–885. - PubMed
    1. Fernandez N, McEnaney R, Marone LK, et al. Multilevel versus isolated endovascular tibial interventions for critical limb ischemia. J Vasc Surg. 2011;54(3):722–729. - PMC - PubMed

Publication types

MeSH terms